SPA
PBYI icon

Sherbrooke Park Advisers’s Puma Biotechnology PBYI Stock Holding History

Sherbrooke Park Advisers’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,527
Closed -$162K – 449
2025
Q3 		$162K Buy
+30,527
New +$129K 0.08% 406
2025
Q2 		– Sell
-12,224
Closed -$36.2K – 710
2025
Q1 		$36.2K Buy
+12,224
New +$38.3K 0.02% 558

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sherbrooke Park Advisers's PBYI Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Puma Biotechnology (PBYI) in Q4 2025, closing a stake of 30,527 shares — an estimated $162K sold.

Sherbrooke Park Advisers first reported a position in PBYI in Q1 2025 and held it in 2 quarters. The position peaked at $162K in Q3 2025. 151 funds tracked by Wall St. Rank hold PBYI as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Puma Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 30,527 Puma Biotechnology shares in Q4 2025, an estimated $162K.
  • Sherbrooke Park Advisers first reported a position in Puma Biotechnology in Q1 2025 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Puma Biotechnology position peaked at $162K in Q3 2025.
  • 151 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.